Catalyst Event
Sanofi (SNY) · Other
From KEDI Palantir Fixed Tech100 Index (KPLTT100)
3/18/2026, 12:00:00 AM
The US FDA granted Breakthrough Therapy designation to Sanofi's venglustat for the treatment of neurological manifestations of type 3 Gaucher disease (GD3).
Korean Translation
미국 FDA, 사노피의 벤글루스타트를 제3형 고셔병(GD3)의 신경학적 증상 치료제로 혁신치료제 지정함.
Related Recent Events
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release is scheduled for June 12, 2026, which is expected to have a high market impact (>=10%) as it provides the next official update on financial performance scheduled.
6/12/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
The next quarterly earnings release on 2026-05-14 is scheduled.
5/14/2026, 12:00:00 AM
COINBASE GLOBAL INC (COIN) · Earnings Release
Coinbase's Q1 2026 earnings release is scheduled for May 7, 2026. Medium importance is estimated as earnings reports are significant events that typically lead to price adjustments, scheduled.
5/7/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet's Q1 2026 earnings release is expected on April 30, 2026. Analysts forecast EPS of approximately $0.62 on revenue of $1.73 billion. Medium importance is estimated as earnings releases typically drive significant price movement, estimated.
4/30/2026, 12:00:00 AM
Western Digital Corp (WDC) · Earnings Release
Fiscal third-quarter 2026 earnings release on April 29, 2026, is scheduled. Analysts forecast strong year-over-year growth, with consensus EPS estimates around $2.30-$2.34 forecasted. High impact (≥10%) is estimated and scheduled.
4/29/2026, 12:00:00 AM